Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Biotechnology

Healthcare
$1.86 -1.41%

-$0.02 today

Market cap
$141.41M
Beta
2.08
P/E (TTM)
-25.1
EPS (TTM)
-$0.06
52W Low $1.43High $67.00

Volume 0.07M

Average 0.10M

MENS Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS

Total Equity · Q4 FY2025 · quarter ended Dec 2025

Total equity remains negative

Q4 FY2025 total equity was -$24.91M, compared with -$36.52M a year earlier.

Context

  • Total equity amounted to 119.9% of total assets at the end of Q4 FY2025, down 453.8 pp from a year earlier.
  • Total equity grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +31.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$24.91M— QoQ
Last fiscal yearDec 2025
-$24.91M+31.8% YoY
Year agoDec 2024
-$36.52M+31.8% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.8%——
1 year+31.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
(24.91M) USD
Year-over-year change
+31.8%

Total Equity vs competitors

How MENS compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +31.8% is the 5th highest of 11, against a peer median of +26.0%.
  • Total equity amounts to 119.9% of total assets for MENS, versus a peer median of 73.2%.
MENS Competitors
Total Equity for MENS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AAPGAscentage Pharma Group InternationalDec 2025CN¥1.34B CNY+387.0%+48.4%33.7%
LEGNLegend Biotech CorporationSep 2026$1.27B USD+25.9%+10.4%75.7%
APGEApogee Therapeutics, Inc.Jun 2026$1.19B USD+92.9%+85.3%89.4%
XENEXenon Pharmaceuticals Inc.Sep 2026$1.15B USD+104.9%-6.9%95.5%
CGONCG Oncology, Inc. Common stockSep 2026$990.97M USD+44.1%+81.8%94.7%
DYNDyne Therapeutics, Inc.Jun 2026$702.15M USD+22.9%+56.8%70.6%
CNTACentessa Pharmaceuticals plcMar 2026$487.35M USD+26.2%+16.2%75.9%
TVTXTravere Therapeutics, Inc.Sep 2026$22.58M USD-69.3%+38.9%2.7%
CELCCelcuity Inc.Jun 2026-$12.78M USD-128.8%-9.1%1.5%
MENSJyong Biotech Ltd. Ordinary SharesDec 2025-$24.91M USD+31.8%—119.9%
RAREUltragenyx Pharmaceutical Inc.Mar 2026-$229M USD-251.4%—17.7%
Peer median (excluding MENS) —+26.0%+38.9%73.2%

Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents551K718K177K98K1.18M
Short-term Investments1.83M94K000
Net Receivables000013.51M
Inventory00000
Other Current Assets263K1.65M1.66M108K854K
Total Current Assets2.65M2.46M1.84M206K15.54M
Property, Plant & Equipment (Net)6.78M6M3.54M3.19M5.23M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets8K283K2.87M2.97M6K
Total Non-current Assets6.78M6.28M6.41M6.16M5.24M
Total Assets9.43M8.75M8.25M6.37M20.78M
Account Payables46K4K2K3K2K
Short-term Debt4.93M7.65M7.97M7.28M8.36M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities23K4.22M4.99M3.33M26.31M
Total Current Liabilities6.29M12.91M14.26M12.13M34.81M
Long-term Debt6.26M6.32M8.52M10.68M10.16M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities19.86M19.04M19.47M20.06M688K
Total Non-current Liabilities26.46M25.47M28.06M30.76M10.87M
Total Liabilities32.76M38.38M42.32M42.89M45.68M
Common Stock1K1K1K1K1K
Retained Earnings(19.03M)(25.66M)(30.06M)(33.08M)(37.75M)
Accumulated OCI266K590K548K1.12M682K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(23.33M)(29.63M)(34.07M)(36.52M)(24.91M)
Total Debt11.79M14.25M16.69M18.14M18.55M
Net Debt11.24M13.53M16.51M18.04M17.37M

Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Intrinsic Alpha fair value

Locked

Current Price

$1.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.